ContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

EDISON, N.J., Aug. 30, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. CTRV, a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today it will be featured as a presenting company at the 20^th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4-6, at the St. Regis New York Hotel in New York City.

Theresa Matkovits, Chief Operating Officer of ContraVir, will provide an overview of the company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the company's presentation, please click on the following link (www.rodmanevents.com ) to register for the conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the company.

Event:  20^th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC

Date:  September 6, 2018

Time:  3:00PM (Eastern Time)

Location:  Louis XVI A (2^nd floor); St. Regis New York Hotel in New York City

About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative oral therapy for hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™, a direct acting antiviral (DAA) nucleotide analog lipid prodrug of tenofovir (TFV), is designed to deliver higher hepatic intracellular concentrations of the active tenofovir species (tenofovir diphosphate) while reducing concentrations of tenofovir outside the liver, causing fewer off-target toxicities and side-effects. CRV431, the other anti-HBV compound, is a host-targeting antiviral (HTA) next-generation cyclophilin inhibitor with a novel chemical structure that optimizes the selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg), while offering additional benefits to mitigate liver disease. For more information, please visit www.contravir.com.

For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; +1 (732) 902-4028